The heart: an end-organ of GH action

Department of Molecular and Clinical Endocrinology and Oncology, 'Federico II' University, via S. Pansini 5, 80131 Naples, Italy. colao@unina.it

Several experimental and clinical studies have indicate that the heart is an end-organ of GH action. Patients with either childhood- or adulthood-onset GH deficiency (GHD) have abnormalities of cardiac structure and function, such as reduced cardiac mass, impaired diastolic filling and reduced left ventricular response at peak exercise. These cardiovascular abnormalities can be reversed, at least partially, after GH replacement therapy. On the other hand, the chronic overproduction of GH and IGF-I in acromegaly leads to the development of a specific cardiomyopathy. Concentric cardiac hypertrophy occurs in more than two-thirds of patients at diagnosis and is commonly associated with diastolic dysfunction. In later stages, impaired systolic function ending in heart failure can occur if GH/IGF-I excess is not controlled. Additionally, acromegalic cardiomyopathy is complicated by abnormalities of cardiac rhythm and cardiac valves. Successful control of acromegaly is accompanied by a decrease of the left ventricular mass and improvement of cardiac function. These beneficial effects appear earlier in young patients with short disease duration than in elderly patients. In conclusion, GH and IGF-I play a main role in the regulation of cardiac development and performance.

This article has been cited by other articles:

				L. Groban, H. Jobe, M. Lin, T. Houle, D. A. Kitzman, and W. Sonntag Effects of Short-Term Treadmill Exercise Training or Growth Hormone Supplementation on Diastolic Function and Exercise Tolerance in Old Rats J. Gerontol. A Biol. Sci. Med. Sci., September 1, 2008; 63(9): 911 - 920. [Abstract] [Full Text] [PDF]

				N. Kloting, L. Koch, T. Wunderlich, M. Kern, K. Ruschke, W. Krone, J. C. Bruning, and M. Bluher Autocrine IGF-1 Action in Adipocytes Controls Systemic IGF-1 Concentrations and Growth Diabetes, August 1, 2008; 57(8): 2074 - 2082. [Abstract] [Full Text] [PDF]

				E. R. Schwarz, P. Jammula, R. Gupta, and S. Rosanio A Case and Review of Acromegaly-Induced Cardiomyopathy and the Relationship Between Growth Hormone and Heart Failure: Cause or Cure or Neither or Both? Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2006; 11(4): 232 - 244. [Abstract] [PDF]

				B. DeBosch, N. Sambandam, C. Weinheimer, M. Courtois, and A. J. Muslin Akt2 Regulates Cardiac Metabolism and Cardiomyocyte Survival J. Biol. Chem., October 27, 2006; 281(43): 32841 - 32851. [Abstract] [Full Text] [PDF]

				L. Groban, N. A. Pailes, C. D. L. Bennett, C. S. Carter, M. C. Chappell, D. W. Kitzman, and W. E. Sonntag Growth Hormone Replacement Attenuates Diastolic Dysfunction and Cardiac Angiotensin II Expression in Senescent Rats J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2006; 61(1): 28 - 35. [Abstract] [Full Text] [PDF]

				J Ayuk and M C Sheppard Growth hormone and its disorders Postgrad. Med. J., January 1, 2006; 82(963): 24 - 30. [Abstract] [Full Text] [PDF]

				X. Peng, B. Chen, C. C. Lim, and D. B. Sawyer The Cardiotoxicology of Anthracycline Chemotherapeutics: TRANSLATING MOLECULAR MECHANISM INTO PREVENTATIVE MEDICINE Mol. Interv., June 1, 2005; 5(3): 163 - 171. [Abstract] [Full Text] [PDF]